Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023

BUY
$0.28 - $0.44 $21,160 - $33,252
75,573 Added 1669.38%
80,100 $35,000
Q3 2022

Nov 10, 2022

SELL
$0.28 - $0.41 $14,280 - $20,910
-51,002 Reduced 91.85%
4,527 $1,000
Q2 2022

Aug 10, 2022

BUY
$0.25 - $0.73 $13,882 - $40,536
55,529 New
55,529 $20,000
Q1 2022

May 16, 2022

SELL
$0.55 - $1.47 $11,337 - $30,301
-20,613 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$1.29 - $2.36 $26,590 - $48,646
20,613 New
20,613 $26,000
Q2 2021

Aug 13, 2021

SELL
$2.07 - $2.89 $85,905 - $119,935
-41,500 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$2.34 - $3.44 $75,111 - $110,420
32,099 Added 341.44%
41,500 $108,000
Q4 2020

Feb 11, 2021

BUY
$1.91 - $5.63 $17,955 - $52,927
9,401 New
9,401 $26,000

Others Institutions Holding SIOX

About Sio Gene Therapies Inc.


  • Ticker SIOX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,975,200
  • Description
  • Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...
More about SIOX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.